HeartLung.AI will be the only company at ESC Congress 2026 presenting this high number of accepted scientific studies. The achievement reflects the strength of the company’s research program and the ...

The pattern of valvular heart disease in India is shifting. Degenerative tricuspid aortic stenosis now accounts for 58.1% of acquired isolated aortic stenosis (AS) cases (mean age 63.2 ± ...

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has enrolled and successfully treated the first US patients in the global ...

Epiaortic ultrasonography has high sensitivity for the detection of atherosclerosis. In several studies, the technique has identified atherosclerosis of the ascending aorta as the major risk factor ...

“Following CMS approval, the Anteris team and our physician partners worked closely together to achieve first patient enrollments within the week. This marks a major milestone for the PARADIGM Trial ...

Anteris Technologies had first patients enrolled and successfully treated in a global pivotal trial of its DurAVR valve.

Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to announce that the company has reached a major ...

Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...

The analysis, based on Medicare data, also showed women have higher risks of complications and early mortality than men.

The S&P/ASX Small Ordinaries [XSO] closed at 3,458.80, gaining 15.20 points or 0.44% in the latest session. Over the past ...

It’s going to be a busy 4 days in Paris, with 166 late-breaking studies and nearly 2,000 clinical cases to be presented.

Why it matters: Millions live with undiagnosed valvular heart disease, which can lead to heart failure, stroke, or death if untreated. What’s causing it: Valve narrowing and calcification can result ...